KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Short-term Investments (2021 - 2025)

Bionano Genomics' Short-term Investments history spans 5 years, with the latest figure at $10.3 million for Q3 2025.

  • For Q3 2025, Short-term Investments rose 224.87% year-over-year to $10.3 million; the TTM value through Sep 2025 reached $10.3 million, up 224.87%, while the annual FY2024 figure was $302000.0, 99.38% down from the prior year.
  • Short-term Investments for Q3 2025 was $10.3 million at Bionano Genomics, down from $11.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $226.0 million in Q4 2021 and bottomed at $302000.0 in Q4 2024.
  • The 5-year median for Short-term Investments is $55.5 million (2023), against an average of $81.7 million.
  • The largest annual shift saw Short-term Investments plummeted 99.38% in 2024 before it skyrocketed 224.87% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $226.0 million in 2021, then crashed by 52.18% to $108.1 million in 2022, then plummeted by 54.83% to $48.8 million in 2023, then tumbled by 99.38% to $302000.0 in 2024, then soared by 3299.34% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Short-term Investments are $10.3 million (Q3 2025), $11.0 million (Q2 2025), and $14.6 million (Q1 2025).